Associated Genetic Biomarkers
XRCC3 is altered in 0.81% of all cancers with colon adenocarcinoma, endometrial endometrioid adenocarcinoma, and lung adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in XRCC3 are XRCC3 Mutation (0.15%), XRCC3 T52M (0.01%), XRCC3 Amplification (0.00%), XRCC3 E182K (0.00%), and XRCC3 G271R (0.00%) .
XRCC3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains XRCC3 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with XRCC3 status in the inclusion eligibility criteria most commonly target urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is XRCC3 Mutation .
Olaparib is the most frequent therapy in trials with XRCC3 as an inclusion criteria .
Significance of XRCC3 in Diseases
Urothelial Carcinoma +
XRCC3 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC3 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.